Widely used:Recently Viewed
Clear All
$0.00
$0.00
(-33.33%)
As on 16-Oct-2024 11:18EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-94.10 Mln
EBITDA
$-110.20 Mln
Net Profit
$-48.47 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
eFFECTOR Therapeutics Inc. Warrant (EFTRW)
| -99.59 | -- | -88.68 | -99.57 | -93.03 | -- | -- |
|
BSE Sensex*
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
2023
|
|
|---|---|
|
eFFECTOR Therapeutics Inc. Warrant (EFTRW)
| -9.87 |
|
BSE Sensex
| 18.74 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral... small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California. Read more
CEO, President & Director
Dr. Stephen T. Worland Ph.D.
CEO, President & Director
Dr. Stephen T. Worland Ph.D.
Headquarters
Solana Beach, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of eFFECTOR Therapeutics Inc Warrant (EFTRW) is $0.00 (NASDAQ) as of 16-Oct-2024 11:18 EDT. eFFECTOR Therapeutics Inc Warrant (EFTRW) has given a return of -93.03% in the last 3 years.
eFFECTOR Therapeutics Inc Warrant (EFTRW) has a market capitalisation of -- as on 16-Oct-2024. As per Value Research classification, it is a company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the eFFECTOR Therapeutics Inc Warrant (EFTRW) and enter the required number of quantities and click on buy to purchase the shares of eFFECTOR Therapeutics Inc Warrant (EFTRW).
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
The CEO & director of Dr. Stephen T. Worland Ph.D.. is eFFECTOR Therapeutics Inc Warrant (EFTRW), and CFO & Sr. VP is Dr. Stephen T. Worland Ph.D..
There is no promoter pledging in eFFECTOR Therapeutics Inc Warrant (EFTRW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| eFFECTOR Therapeutics Inc. Warrant (EFTRW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of eFFECTOR Therapeutics Inc Warrant (EFTRW) was $0 Mln.
